- 中文名稱
Anti-Human VEGFR1-14/Flt1-14 (peptide), soluble
- 英文名字
- Anti-Human VEGFR1-14/Flt1-14 (peptide), soluble
- 供應(yīng)商
- ReliaTech
- 產(chǎn)品貨號(hào)
- 101-M29
- 產(chǎn)品報(bào)價(jià)
- ￥詢價(jià)/100ug
- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購(gòu)買方式
- 90%產(chǎn)品中國(guó)有現(xiàn)貨庫(kù)存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868
- 產(chǎn)品新聞
- 背景資料
- A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.
- 應(yīng)用類型
- ELISA, WB
- 免疫原
- 該Anti-Human VEGFR1-14/Flt1-14 (peptide), soluble的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 來源宿主
- Mouse
- 反應(yīng)性
- 該Anti-Human VEGFR1-14/Flt1-14 (peptide), soluble的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 保存建議
- 該Anti-Human VEGFR1-14/Flt1-14 (peptide), soluble的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 其他
- ReliaTech全稱為受體配體技術(shù)有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國(guó)不倫瑞克，是一家后基因組生物技術(shù)公司。ReliaTech主要專注于受體和配體的發(fā)現(xiàn)與研究。此外，ReliaTech也開發(fā)應(yīng)用于血管與淋巴管生成研究的相關(guān)高品質(zhì)試劑。目前ReliaTech提供近2800款產(chǎn)品，產(chǎn)品線主要包括重組蛋白(細(xì)胞因子、生長(zhǎng)因子、可溶性受體)、抗體、ELISA試劑盒等。
- 注意
-
該頁(yè)面的中文產(chǎn)品信息的翻譯，僅供參考。準(zhǔn)確的產(chǎn)品信息請(qǐng)以廠家的英文說明書為準(zhǔn)。下單前，請(qǐng)瀏覽說明書確認(rèn)。
-
